Navigation Links
Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
Date:11/10/2011

PALO ALTO, Calif., Nov. 10, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today two clinical presentations at the 53rd Annual Meeting of the American Society of Hematology in San Diego, California. Details of the presentations are as follows:

  • Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS); Azra Raza, MD; Naomi Galili, PhD; Deborah Mulford, MD; Scott E. Smith, MD, PhD, FACP; Gail Brown, MD; Lisa Meng, PhD; David P. Steensma, MD; Roger M Lyons, MD; Ralph Boccia, MD; Mikkael A. Sekeres, MD, MS; Guillermo Garcia-Manero, MD; and Ruben A. Mesa, MD
    • Abstract #2778 – Myelodysplastic Syndromes: Poster II; Sunday, December 11, 2011, 6:00 PM -8:00 PM; San Diego Convention Center, Hall GH
  • Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199); Naomi Galili, Ph.D.; Pablo Tamayo, PhD; Olga B Botvinnik; Jill P Mesirov, PhD; Jennifer Zikria, MD; Gail Brown, MD and Azra Raza, MD
    • Abstract #2779 – Myelodysplastic Syndromes: Poster II; Sunday, December 11, 2011, 6:00 PM - 8:00 PM; San Diego Convention Center, Hall GH

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Third Quarter 2011 Financial Results
2. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
3. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
5. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
6. Telik Announces First Quarter 2011 Financial Results
7. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
8. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
9. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
10. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
11. Telik Announces Presentation at American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and ... ... valued at US$ 7,167.6 Mn in 2015, and is expected ... CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under Dr. ... board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a ... and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts ... hospital and decide to donate. , “Women’s Hospital at Renaissance has been a ...
(Date:4/28/2017)... Yorba Linda, Ca (PRWEB) , ... April 28, ... ... entities with cardiac or hERG liability could substantially improve drug safety and minimize ... will be provided for validating ion channel inhibition using cell lines and for ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... Pensacola, FL (PRWEB) , ... April 28, 2017 ... ... Tampa, Florida are conducting a pilot study of ActiGraph’s CentrePoint Data ... ActiGraph is a leading provider of clinical-grade wearable activity and sleep monitoring solutions ...
Breaking Medicine News(10 mins):